AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28323950 — intervention group
Group type: COMPARATOR
Intervention: Simple resistance activity interruptions (SRA)
Number of subjects: 21
Study 28323950 — intervention group
Group type: EXPERIMENTAL
Intervention: Uninterrupted sitting (SIT)
Number of subjects: 21
Study 25322868 — intervention group
Group type: EXPERIMENTAL
Intervention: Wii group
Number of subjects: 24
Study 25322868 — intervention group
Group type: EXPERIMENTAL
Intervention: XaviX group
Number of subjects: 24
Study 25322868 — intervention group
Group type: COMPARATOR
Intervention: Conventional group
Number of subjects: 24
Study 25322868 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation across groups
Number of subjects: 24
Study 23980348 — intervention group
Group type: EXPERIMENTAL
Intervention: Jinshuibao Capsule (JC) + losartan potassium
Number of subjects: 106
Study 23980348 — intervention group
Group type: COMPARATOR
Intervention: losartan potassium
Number of subjects: 106
Study 21562484 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 50 mg - MDMA 75 mg
Number of subjects: 17
Study 21562484 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol 20 mg - MDMA 75 mg
Number of subjects: 17
Study 21562484 — intervention group
Group type: COMPARATOR
Intervention: Placebo - MDMA 75 mg
Number of subjects: 17
Study 21562484 — intervention group
Group type: COMPARATOR
Intervention: Placebo - Placebo
Number of subjects: 17
Study 21562484 — intervention group
Group type: COMPARATOR
Intervention: Pindolol 20 mg - Placebo
Number of subjects: 17
Study 21562484 — intervention group
Group type: COMPARATOR
Intervention: Ketanserin 50 mg - Placebo
Number of subjects: 17
Study 19447800 — intervention group
Group type: EXPERIMENTAL
Intervention: Sivelestat (0.3 mg/kg/h intravenous)
Number of subjects: 20
Study 17045014 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 microg once per day
Number of subjects: 221
Study 17045014 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium 2 puffs qid
Number of subjects: 221
Study 12766750 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous calcium chloride, n = 13
Number of subjects: 29
Study 12766750 — intervention group
Group type: COMPARATOR
Intervention: Placebo, n = 16
Number of subjects: 29
Study 12766750 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (calcium and placebo)
Number of subjects: 29
Study 10840101 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral vaporization resection of the prostate (TUVRP)
Number of subjects: 68
Study 10840101 — intervention group
Group type: COMPARATOR
Intervention: Standard transurethral prostatectomy (TURP)
Number of subjects: 68
Study 9171125 — intervention group
Group type: EXPERIMENTAL
Intervention: AWR with low-pressure pneumoperitoneum (5 mmHg)
Number of subjects: 20
Study 9171125 — intervention group
Group type: COMPARATOR
Intervention: Conventional pneumoperitoneum (15 mmHg)
Number of subjects: 20
Study 9171125 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 1287557 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal thyrotropin-releasing hormone (TRH) treatment (400 micrograms i.v. every 8 h, one to four doses) plus 12 mg betamethasone (one or two doses)
Number of subjects: 0
Study 1287557 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal thyrotropin-releasing hormone (TRH) treatment
Number of subjects: 0
Study 1287557 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline plus betamethasone)
Number of subjects: 0
Study 4032390 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at loci SP6 and LI4
Number of subjects: 20
Study 4032390 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preparation)
Number of subjects: 20
Study 4032390 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 20
Study 29533397 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-day single dose of low-volume (SSL) polyethylene glycol (PEG)
Number of subjects: 940
Study 29533397 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen (split dose of 4L PEG)
Number of subjects: 940
Study 26564575 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular exercise (NEMEX) program, performed in groups twice weekly for 8 weeks, consisting of 11 exercises focusing on joint stability and neuromuscular control.
Number of subjects: 0
Study 24917452 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume-time curve technique
Number of subjects: 450
Study 24917452 — intervention group
Group type: COMPARATOR
Intervention: MOV technique
Number of subjects: 450
Study 23416449 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivoxel pattern analyses on fMRI data
Number of subjects: 0
Study 23416449 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatially distinct areas of the medial orbitofrontal cortex
Number of subjects: 0
Study 19786722 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injections (BTIs)
Number of subjects: 15
Study 19786722 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 15
Study 18256460 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziyuglycoside I (50 muM)
Number of subjects: 0
Study 18256460 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation containing ziyuglycoside I
Number of subjects: 0
Study 16185242 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained teachers diagnosing presumptive malaria
Number of subjects: 0
Study 16185242 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained teachers treating diagnosed cases
Number of subjects: 0
Study 16185242 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-packaging of antimalarial drug
Number of subjects: 0
Study 16185242 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-packaging of chloroquine
Number of subjects: 0
Study 12363118 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized stepwise drug treatment regimen (SSTR)
Number of subjects: 248
Study 9520889 — intervention group
Group type: EXPERIMENTAL
Intervention: Home based rehabilitation program (27 patients)
Number of subjects: 54
Study 9520889 — intervention group
Group type: COMPARATOR
Intervention: Clinic based rehabilitation program (27 patients)
Number of subjects: 54
Study 7650502 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer note-taking by Physician B
Number of subjects: 60
Study 7650502 — intervention group
Group type: COMPARATOR
Intervention: Handwritten note-taking by Physician A
Number of subjects: 60
Study 2667628 — intervention group
Group type: EXPERIMENTAL
Intervention: Kobayashi silicone cup ventouse
Number of subjects: 264
Study 2667628 — intervention group
Group type: COMPARATOR
Intervention: Forceps
Number of subjects: 264
Study 60209 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial oral dose of 900 mg propafenon
Number of subjects: 34
Study 60209 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dose of 300 mg propafenon at eight-hourly intervals
Number of subjects: 34
Study 60209 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0-1.5 mg propafenon per kg body weight by quick infusion
Number of subjects: 34
Study 60209 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenon administered synchronously by the oral route
Number of subjects: 34
Study 30971234 — intervention group
Group type: EXPERIMENTAL
Intervention: Holistic physical exercise training intervention once weekly for 15 weeks
Number of subjects: 31
Study 30971234 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-exercising)
Number of subjects: 31
Study 30971234 — intervention group
Group type: EXPERIMENTAL
Intervention: Holistic physical exercise training intervention
Number of subjects: 31
Study 30480213 — intervention group
Group type: EXPERIMENTAL
Intervention: Video self-assessment
Number of subjects: 16
Study 30480213 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard practice)
Number of subjects: 16
Study 27427132 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plan containing 1,500mg of sodium providing 2,000 calories, advised not to consume sodium-rich foods.
Number of subjects: 1492
Study 27427132 — intervention group
Group type: COMPARATOR
Intervention: Routine diet (control group), advised not to consume sodium-rich foods.
Number of subjects: 1492
Study 27427132 — intervention group
Group type: COMPARATOR
Intervention: Comparison between intervention and control groups.
Number of subjects: 1492
Study 25188356 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex working memory training program incorporating verbal and spatial tasks
Number of subjects: 0
Study 25188356 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 22946673 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 114
Study 22946673 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin with associated treatments (antidepressants and mood stabilizers)
Number of subjects: 114
Study 22946673 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin with benzodiazepines
Number of subjects: 114
Study 19174803 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency thermal ablation (RF)
Number of subjects: 701
Study 19174803 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous ethanol injection (PEI)
Number of subjects: 701
Study 19174803 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency thermal ablation (RF) and Percutaneous ethanol injection (PEI)
Number of subjects: 701
Study 17497466 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone plus Losartan (PSL + LST)
Number of subjects: 38
Study 17497466 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone alone (PSL)
Number of subjects: 38
Study 15764256 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (25 mg)
Number of subjects: 54
Study 15764256 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg)
Number of subjects: 54
Study 15764256 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (Losartan 25 mg and Enalapril 10 mg)
Number of subjects: 54
Study 12476017 — intervention group
Group type: EXPERIMENTAL
Intervention: KET 2% shampoo
Number of subjects: 343
Study 12476017 — intervention group
Group type: COMPARATOR
Intervention: ZPT 1% shampoo
Number of subjects: 343
Study 9667559 — intervention group
Group type: EXPERIMENTAL
Intervention: Contour technique
Number of subjects: 16
Study 9667559 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual outlining method
Number of subjects: 16
Study 7814827 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimeldine
Number of subjects: 55
Study 7814827 — intervention group
Group type: EXPERIMENTAL
Intervention: Norzimeldine
Number of subjects: 55
Study 7814827 — intervention group
Group type: EXPERIMENTAL
Intervention: CPP 200
Number of subjects: 55
Study 7814827 — intervention group
Group type: COMPARATOR
Intervention: Control (Zimeldine without HSS symptoms)
Number of subjects: 55
Study 2787289 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood cardioplegia
Number of subjects: 55
Study 2787289 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid cardioplegia
Number of subjects: 55
Study 59017 — intervention group
Group type: EXPERIMENTAL
Intervention: Human diploid cell strain rabies vaccine (0.4 ml on day 0)
Number of subjects: 114
Study 59017 — intervention group
Group type: EXPERIMENTAL
Intervention: Human diploid cell strain rabies vaccine (0‐1 ml on days 0, 1, 2, 3)
Number of subjects: 114
Study 59017 — intervention group
Group type: EXPERIMENTAL
Intervention: Human diploid cell strain rabies vaccine (0‐1 ml on days 0, 3, 7, and 14)
Number of subjects: 114
Study 59017 — intervention group
Group type: EXPERIMENTAL
Intervention: Human diploid cell strain rabies vaccine (0.1 ml into each limb on day 0)
Number of subjects: 114
Study 31239644 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate (Group E, n=40)
Number of subjects: 80
Study 31239644 — intervention group
Group type: COMPARATOR
Intervention: Propofol (Group P, n=40)
Number of subjects: 80
Study 31239644 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate (Group E)
Number of subjects: 80
Study 31239644 — intervention group
Group type: COMPARATOR
Intervention: Propofol (Group P)
Number of subjects: 80
Study 25267551 — intervention group
Group type: EXPERIMENTAL
Intervention: Marginal mean models fit with generalized estimating equations
Number of subjects: 0
Study 25267551 — intervention group
Group type: COMPARATOR
Intervention: Standard generalized estimating equation sandwich variance estimator
Number of subjects: 0
Study 25267551 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-sample corrections to generalized estimating equations
Number of subjects: 0
Study 25873101 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus acupuncture
Number of subjects: 20
Study 25873101 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 20
Study 24038728 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of d‐cycloserine (DCS) administered 1 hr prior to sessions 3‐7, n = 87
Number of subjects: 169
Study 24038728 — intervention group
Group type: COMPARATOR
Intervention: Pill placebo administered 1 hr prior to sessions 3‐7, n = 82
Number of subjects: 169
Study 20410904 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri
Number of subjects: 249
Study 20410904 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus
Number of subjects: 249
Study 20410904 — intervention group
Group type: COMPARATOR
Intervention: No supplementation (Control)
Number of subjects: 249
Study 20031809 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based psychosocial intervention program (20 sessions over a year)
Number of subjects: 237
Study 20031809 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 237
Study 20031809 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based psychosocial intervention program
Number of subjects: 237
Study 17178485 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 1 mg/kg
Number of subjects: 90
Study 17178485 — intervention group
Group type: COMPARATOR
Intervention: Ketoprofen 100 mg
Number of subjects: 90
Study 15064254 — intervention group
Group type: COMPARATOR
Intervention: Standard information leaflet about anaesthesia (Group 1)
Number of subjects: 85
Study 15064254 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard leaflet plus manufacturers' patient information leaflets for propofol and remifentanil (Group 2)
Number of subjects: 85
Study 11791892 — intervention group
Group type: EXPERIMENTAL
Intervention: FP-spacer: fluticasone pressurised metered dose inhaler (Flixotide 250 microg ex-valve per actuation), eight puffs via a primed Volumatic 750-ml spacer.
Number of subjects: 14
Study 11791892 — intervention group
Group type: EXPERIMENTAL
Intervention: FP-neb: Flixotide Nebule 2 mg/2 ml via Pari LC Plus nebuliser.
Number of subjects: 14
Study 11791892 — intervention group
Group type: COMPARATOR
Intervention: Placebo nebuliser
Number of subjects: 14
Study 9230825 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost (50 mg/L)
Number of subjects: 20
Study 9230825 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine salicylate (8 mg/mL)
Number of subjects: 20
Study 9230825 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost and Physostigmine combination
Number of subjects: 20
Study 9230825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1773364 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil administered a few seconds before propofol injection
Number of subjects: 40
Study 1773364 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil administered just after propofol injection
Number of subjects: 40
Study 1773364 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus injection of alfentanil
Number of subjects: 40
Study 1773364 — intervention group
Group type: EXPERIMENTAL
Intervention: Dosages of alfentanil in plasma
Number of subjects: 40
Study 6119510 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic injection sclerotherapy
Number of subjects: 107
Study 6119510 — intervention group
Group type: COMPARATOR
Intervention: Standard medical management
Number of subjects: 107
Study 30442084 — intervention group
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block before fistula surgery
Number of subjects: 105
Study 30442084 — intervention group
Group type: COMPARATOR
Intervention: Stellate ganglion block after surgery
Number of subjects: 105
Study 30442084 — intervention group
Group type: COMPARATOR
Intervention: Control group without any block
Number of subjects: 105
Study 29025888 — intervention group
Group type: EXPERIMENTAL
Intervention: Erdosteine 300 mg twice daily
Number of subjects: 445
Study 29025888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 445
Study 26703279 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release dexamethasone
Number of subjects: 100
Study 26703279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 25410076 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmon calcitonin, 50 IU, subcutaneous injection, 1 time a day for 15 days
Number of subjects: 0
Study 25410076 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmon calcitonin, 50 IU, subcutaneous injection, 1 time every 2 days for 30 days
Number of subjects: 0
Study 25410076 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmon calcitonin, 50 IU, subcutaneous injection, 1 time every 3 days for 90 days
Number of subjects: 0
Study 22641256 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchodilator therapy
Number of subjects: 12
Study 20713478 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938 (10^8 colony‐forming units)
Number of subjects: 50
Study 18346996 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel (n = 48)
Number of subjects: 71
Study 18346996 — intervention group
Group type: COMPARATOR
Intervention: Control (standard care, n = 23)
Number of subjects: 71
Study 16167973 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.2 g co-amoxiclav (or 2 g cefotaxime if penicillin-allergic)
Number of subjects: 99
Study 16167973 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 12207636 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRI)
Number of subjects: 350
Study 12207636 — intervention group
Group type: COMPARATOR
Intervention: Tricyclic antidepressants (TCA)
Number of subjects: 350
Study 12207636 — intervention group
Group type: COMPARATOR
Intervention: No antidepressants
Number of subjects: 350
Study 10334546 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral F‐AMP 50 mg
Number of subjects: 18
Study 10334546 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral F‐AMP 70 mg
Number of subjects: 18
Study 10334546 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral F‐AMP 90 mg
Number of subjects: 18
Study 10334546 — intervention group
Group type: COMPARATOR
Intervention: Intravenous F‐AMP 50 mg
Number of subjects: 18
Study 10334546 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous F‐AMP 25 mg/m2
Number of subjects: 18
Study 8778603 — intervention group
Group type: EXPERIMENTAL
Intervention: sodium benzoate, alone or in combination with sodium phenylacetate or sodium phenylbutyrate, or sodium phenylbutyrate alone
Number of subjects: 32
Study 8778603 — intervention group
Group type: EXPERIMENTAL
Intervention: sodium phenylacetate or sodium phenylbutyrate treatment
Number of subjects: 32
Study 8778603 — intervention group
Group type: COMPARATOR
Intervention: not specified
Number of subjects: 32
Study 8778603 — intervention group
Group type: EXPERIMENTAL
Intervention: drugs that activate new pathways of waste‐nitrogen excretion
Number of subjects: 32
Study 1405170 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin (ADM) group; intravesical instillation with 50 mg of ADM dissolved in 100 ml physiological saline.
Number of subjects: 144
Study 1405170 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC) group; intravesical instillation with 30 mg of MMC dissolved in 100 ml of physiological saline.
Number of subjects: 144
Study 1405170 — intervention group
Group type: COMPARATOR
Intervention: Control group; transurethral resection or transurethral coagulation only.
Number of subjects: 144
Study 2409845 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% albumin (group A)
Number of subjects: 15
Study 2409845 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (group H)
Number of subjects: 15
Study 2409845 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's solution (group C)
Number of subjects: 15
Study 30919040 — intervention group
Group type: EXPERIMENTAL
Intervention: Parallel antenna placement (group A)
Number of subjects: 71
Study 30919040 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossed antenna placement (group B)
Number of subjects: 71
Study 30595274 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance training (CART) 5 times/week for 4 weeks
Number of subjects: 28
Study 30595274 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment without any supervised exercise intervention
Number of subjects: 28
Study 27618080 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive nutrition education
Number of subjects: 196
Study 27618080 — intervention group
Group type: COMPARATOR
Intervention: Usual nutrition education (Control)
Number of subjects: 196
Study 24667905 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive cognitive training for 10 days over 2 weeks with 4 to 5 hours of training each day
Number of subjects: 21
Study 24667905 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive cognitive training
Number of subjects: 21
Study 22323895 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin extended-release/simvastatin (NER/S) 1000/40 mg/day for 4 weeks followed by 2000/40 mg/day for 8 weeks
Number of subjects: 137
Study 22323895 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin extended-release/simvastatin (NER/S)
Number of subjects: 137
Study 22323895 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 40 mg/day for 12 weeks
Number of subjects: 137
Study 19804455 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-dose cytarabine for 4 days followed by gemtuzumab ozogamicin on day 5 (Arm A)
Number of subjects: 82
Study 19804455 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-dose cytarabine for 4 days combined with liposomal daunorubicin for 3 days (Arm B)
Number of subjects: 82
Study 19804455 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytarabine given for 5 days combined with cyclophosphamide for 3 days and topotecan by continuous infusion for 5 days (Arm C)
Number of subjects: 82